

Michael Konkell, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page 7

Marked-up versions of amended claims 2, 8-10, 17-19 and 38 showing the changes made are attached hereto as **Exhibit 1**.

#### REMARKS

Claims 2-4, 7-12 and 14-42 were pending in the subject application. By this Amendment, applicants have canceled claims 14 and 15, amended claims 2, 8-10, 17-19 and 38, and added new claims 43-44. Accordingly, upon entry of this Amendment, claims 2-4, 7-12 and 16-44, as amended, will be pending and presently under examination.

Applicants maintain that the amendments to claims 2, 8-10, 17-19 and 38 and the addition of new claims 43 and 44 do not raise any issue of new matter. Support for amended claim 2 may be found inter alia in the specification, as originally filed, on page 15, lines 14-22. Support for amended claims 8-10 may be found inter alia in the specification, as originally filed, on page 16, lines 5-10; and on page 18, lines 12-19. Support for amended claims 17-19 may be found inter alia in the specification, as originally filed, on page 20, lines 1-5 and on page 22, lines 25-30. Support for amended claim 38 may be found inter alia in the specification, as originally filed, on page 16, line 3 through page 18, line 20; and on page 34, line 3 through page 35, line 7.

Support for new claims 43 and 44 may be found inter alia in the specification, as originally filed, on page 24, lines 7-9.

#### Previously Allowed Claims

On page 2 of the March 25, 2003 Office Action, the Examiner stated that the allowance of claims 38-42 in the office action of

Michael Konkell, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page 8

paper no. 11 was in error because these claims contained non-elected subject matter.

#### New Objections

On page 2 of the March 25, 2003 Office Action, the Examiner alleged that claims 2-4 and 38-42 contain non-elected subject matter, i.e., they encompass compounds that are larger in scope than the elected group I, which is a compound of claim 7, where X is N. The Examiner stated that if these claims were limited solely to the elected group, they would be allowable.

In response, in an attempt to advance the prosecution of the application but without conceding the correctness of the Examiner, applicants have amended claims 2 and 38 to recite the formula of the compound or antagonist, respectively. Applicants maintain that claims 2-4 and 38-42 are limited to the elected group as required by the Examiner, and respectfully request that this objection be withdrawn.

On page 3 of the March 25, 2003 Office Action, the Examiner alleged that claims 8-10 and 17-19 lack antecedent basis because claims 8-10 and 17-19 depict an "X" moiety which does not appear in the claims from which they depend, i.e., claims 7 and 16. The Examiner stated that amending said claims to delete the "X" moiety and replacing said moiety with "N" would obviate the above objections.

In response, in an attempt to advance the prosecution of the subject application, applicants have amended claims 8-10 and 17-19 by replacing the "X" moiety with "N". Applicants maintain that dependent claims 8-10 and 17-19, as amended, contain the necessary antecedent basis in claim 7 and 16. Accordingly, applicants respectively request that the Examiner reconsider and

Michael Konkell, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page 9

withdraw this ground of objection.

On page 3 of the March 25, 2003 Office Action, the Examiner objected to claims 14-15 as being dependent on a later occurring claim 16. The Examiner stated that amending said claims to depend from a previous claim would obviate the above objections.

In response, in an attempt to advance the prosecution of the subject application but without conceding the correctness of the Examiner's position or the need for amendment, applicants have canceled claims 14 and 15 and have added new claims 43 and 44. New claims 43 and 44 depend from claim 16. Accordingly, applicants respectfully request that this objection be withdrawn.

#### Allowed Claims

The Examiner acknowledged that claims 7, 11, 12 and 20-37 are allowed.


In summary, in light of the remarks made above, applicants respectively request the examiner to reconsider and withdraw the grounds of objections set forth in the March 25, 2003 Office Action.


If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page 10

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
 John P. White Reg. No. 28,678	6/24/03 Date


  
John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

Marked-Up Version of the Claims



Additions are indicated by underlining; deletions are indicated by brackets.

--2. (Twice Amended) [A method of inhibiting activation of a human  $\alpha_{1d}$  adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor] The method of claim 7, wherein the compound binds to the human  $\alpha_{1d}$  adrenergic receptor with a binding affinity which is at least 25-fold higher than the binding affinity with which the compound binds to (i) a human  $\alpha_{1a}$  adrenergic receptor and (ii) a human  $\alpha_{1b}$  adrenergic receptor, and the compound binds to the human  $\alpha_{1d}$  adrenergic receptor with a binding affinity which is at least ten-fold higher than the binding affinity with which the compound binds to a human 5-HT<sub>1a</sub> receptor.--



--8. (Amended) The method of claim 7, wherein the compound has the structure:





--9. (Amended) The method of claim 8, wherein the compound has the structure:





--10. (Amended) The method of claim 9, wherein the compound has the structure:




--17. (Amended) A compound of claim 16, wherein the compound has the structure:




--18. (Amended) A compound of claim 17, wherein the compound has the structure:



--19. (Amended) A compound of claim 18, wherein the compound has the structure:




--38. (Amended) A method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a  $\alpha_{1d}$  adrenergic antagonist, which binds to the human  $\alpha_{1d}$  adrenergic receptor with a binding affinity which is at least 10-fold higher than the binding affinity with which the compound binds to (i) a human  $\alpha_{1a}$  adrenergic receptor and (ii) a human  $\alpha_{1b}$  adrenergic receptor, and the compound binds to the human  $\alpha_{1d}$  adrenergic receptor with a binding affinity which is at least ten-fold higher than the binding affinity with which the compound binds to a human 5-HT<sub>1a</sub> receptor, wherein the  $\alpha_{1d}$  adrenergic receptor antagonist has the structure:





wherein each m and n is independently an integer from 0 to 2;

wherein each Y and Z is independently



wherein R1 and R2 (i) are independently H, branched or unbranched C<sub>1</sub>-C<sub>6</sub> alkyl or alkoxy, branched or unbranched C<sub>2</sub>-C<sub>6</sub> alkenyl or alkynyl, branched or unbranched C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, hydroxy, substituted or unsubstituted aryl or aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or substituted or unsubstituted heteroaryl or heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the substituent if present is a halogen, CN, nitro, hydroxy, branched or unbranched C<sub>1</sub>-C<sub>6</sub> alkyl or alkoxy group, or branched or unbranched C<sub>2</sub>-C<sub>6</sub> alkenyl or alkynyl group; or (ii) taken together form a substituted or unsubstituted cycloalkyl ring containing 3-10 carbons, wherein the substituent if present is a branched or unbranched C<sub>1</sub>-C<sub>6</sub> alkyl group or branched or unbranched C<sub>2</sub>-C<sub>6</sub> alkenyl or alkynyl group;

wherein R3 is H, branched or unbranched C<sub>1</sub>-C<sub>6</sub> alkyl, branched or unbranched C<sub>2</sub>-C<sub>6</sub> alkenyl or alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkylalkyl, aryl, heteroaryl, aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted C<sub>3</sub>-C<sub>7</sub> cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or substituted heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sub>14</sub>, SR<sub>14</sub>, N(R<sub>14</sub>)<sub>2</sub>, SO<sub>2</sub>N(R<sub>14</sub>)<sub>2</sub>, CO<sub>2</sub>R<sub>14</sub>, SO<sub>3</sub>R<sub>14</sub>, N(R<sub>14</sub>)COR<sub>14</sub>, CON(R<sub>14</sub>)<sub>2</sub>, or N(R<sub>14</sub>)CON(R<sub>14</sub>)<sub>2</sub>;

wherein R4 is H or CH<sub>3</sub>;

wherein R5 is H, branched or unbranched C<sub>1</sub>-C<sub>6</sub> alkyl, branched or unbranched C<sub>2</sub>-C<sub>6</sub> alkenyl or alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkylalkyl, aryl, heteroaryl, aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted C<sub>3</sub>-C<sub>7</sub> cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or substituted heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sub>14</sub>, SR<sub>14</sub>, N(R<sub>14</sub>)<sub>2</sub>, SO<sub>2</sub>N(R<sub>14</sub>)<sub>2</sub>, CO<sub>2</sub>R<sub>14</sub>, SO<sub>3</sub>R<sub>14</sub>, N(R<sub>14</sub>)COR<sub>14</sub>, CON(R<sub>14</sub>)<sub>2</sub>, or N(R<sub>14</sub>)CON(R<sub>14</sub>)<sub>2</sub>;

wherein R6 is H, branched or unbranched C<sub>1</sub>-C<sub>6</sub> alkyl, branched or unbranched C<sub>2</sub>-C<sub>6</sub> alkenyl or alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkylalkyl, aryl, heteroaryl, aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted C<sub>3</sub>-C<sub>7</sub> cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or substituted heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sub>14</sub>, SR<sub>14</sub>, N(R<sub>14</sub>)<sub>2</sub>, SO<sub>2</sub>N(R<sub>14</sub>)<sub>2</sub>, CO<sub>2</sub>R<sub>14</sub>, SO<sub>3</sub>R<sub>14</sub>, N(R<sub>14</sub>)COR<sub>14</sub>, CON(R<sub>14</sub>)<sub>2</sub>, or N(R<sub>14</sub>)CON(R<sub>14</sub>)<sub>2</sub>;

wherein R7 is H, branched or unbranched C<sub>1</sub>-C<sub>6</sub> alkyl, branched or unbranched C<sub>2</sub>-C<sub>6</sub> alkenyl or alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aryl, aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO<sub>2</sub>R<sub>14</sub>, CON(R<sub>14</sub>)<sub>2</sub>, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted aryl, wherein the substituent is N(R<sub>14</sub>)<sub>2</sub>, halogen, OR<sub>14</sub> or SR<sub>14</sub>;

wherein R8 is H or CH<sub>3</sub>;

wherein R10 is H or F; wherein R11 is H, F, Cl, Br, I, CN,  
branched or unbranched C<sub>1</sub>- C<sub>6</sub> alkyl or alkoxy; wherein R13 is H  
or F;

and wherein R14 is independently H or branched or unbranched C<sub>1</sub>-  
C<sub>6</sub> alkyl.--